Track Group, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Derek Cassell
- Full Time Employees
- 91
- Sector
- Technology
- Industry
- Hardware, Equipment & Parts
- Address
- 5th Avenue Station Naperville IL United States of America 60563
- IPO Date
- Dec 15, 2005
- CIK
- 0001045942
- Website
- trackgrp.com
- Similar Companies
- Business
- Track Group, Inc. (TRCK) designs, manufactures, and markets electronic monitoring and location tracking devices for offender management in the criminal justice sector; its core products include ReliAlert XC4 and ReliAlert XC3 one-piece GPS devices with patented two/three-way voice communication, SHADOW RF/GPS hybrid trackers, InTouch smartphone monitoring applications, Empower victim notification systems, BACtrack Mobile alcohol monitoring breathalyzers, and a hardware-agnostic platform offering predictive analytics, software applications, professional monitoring services, accessories, and networking solutions. The company serves government agencies at federal, state, and local levels in the United States, Latin America including Puerto Rico and the Bahamas, Canada, and internationally through subsidiaries in regions such as Israel and formerly Chile. Founded in 1995 and headquartered in Naperville, Illinois, Track Group focuses on security, law enforcement, corrections, and rehabilitation markets with end-to-end solutions integrating real-time tracking, data analytics, and intervention technologies to reduce risk and support re-socialization. Recent developments include the sale of its Chilean subsidiary contributing to revenue adjustments in fiscal 2025 alongside expansions in Illinois, Puerto Rico, and the Bahamas; improved profitability with Adjusted EBITDA rising to $1.8 million in Q3 FY25 from strategic technology investments and operational streamlining; and FY25 revenue guidance of $34.5 million to $35.5 million reflecting ongoing platform enhancements despite reduced assignments in Virginia and Michigan.
Company News
Bill Ackman Says Pershing Square Has Achieved a 20% Gross Annual Return Since Inception and Aims to Keep Beating That Bar. Can His Newly Launched Funds Live Up to the Track Record?
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
C3.ai Reports Strong Q1: Turnaround is On Track, CEO Says
Is Ares Management on Track to Hit Its $750B AUM Target by 2028?
Gas Turbine Prices Are on Track to Nearly Triple. These Stocks Are Cashing In.
Most Investors Fear Bear Markets. My 7-Year Track Record Shows They Should Welcome Them.
Fendt™ Launches 1100 Vario™ MT Gen2 Track Tractor, Momentum™ 80-Foot Planter and 300 Vario Gen5 at 2026 Farm Progress Show
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
Dick's Sporting Goods Stock On Track for Worst Day Ever
VGMS: Multi-Sector Bond ETF By Vanguard, Vanilla Portfolio, Good Yield And Track Record
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
Will Comfort Systems' 47% Same-Store Growth Stay on Track in 2027?
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
Bunker Hill Mining Announces First Stope Blast on Track for Commercial Production in Q4|2026
Ategrity Specialty Insurance: With A Longer Track Record, Possible Multiple Expansion